The p53 tumor suppressor pathway offers attractive opportunities for targeted therapy of neuroblastoma. We will try to initiate a clinical trial with the p53-activating drug nutlin-3 in neuroblastoma, characterize noncoding RNA molecules and SNPs that affect the p53 network in neuroblastoma, investigate how the MYCN oncogene alters the p53 response to chemotherapy, and identify new targets for molecular therapy.